(Q37806692)

23 August 2017

title

Dual-acting angiotensin receptor-neprilysin inhibition (English)

1 reference

23 August 2017

1

0 references

Luis Miguel Ruilope

object named as

Luis M Ruilope

series ordinal

2

0 references

publication date

1 February 2011

1 reference

Current Hypertension Reports

23 August 2017

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

74-78

1 reference

Global burden of hypertension: analysis of worldwide data

23 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-010-0166-7

Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-010-0166-7

Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-010-0166-7

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

12 December 2020

Molecular biology of the natriuretic peptide system: implications for physiology and hypertension

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Vasopeptidase inhibition: a new concept in blood pressure management

1 reference

12 December 2020

Vasopeptidase inhibition: a double-edged sword?

1 reference

12 December 2020

Hypertension treatment and control in five European countries, Canada, and the United States

1 reference

12 December 2020

Omapatrilat: a unique new agent for the treatment of cardiovascular disease.

1 reference

12 December 2020

Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group

1 reference

12 December 2020

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

1 reference

12 December 2020

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

1 reference

12 December 2020

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

1 reference

12 December 2020

2007 Guidelines for the Management of Arterial Hypertension

1 reference

12 December 2020

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects

1 reference

12 December 2020

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

12 December 2020

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

1 reference

12 December 2020

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

12 December 2020

Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II

1 reference

12 December 2020

Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment

1 reference

12 December 2020

1 reference

12 December 2020

Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension

1 reference

12 December 2020

Biology of natriuretic peptides and their receptors

1 reference

12 December 2020

Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase

1 reference

12 December 2020

Effects of omapatrilat in low, normal, and high renin experimental hypertension

1 reference

12 December 2020

10.1007/S11906-010-0166-7

Identifiers

DOI

1 reference

23 August 2017

1 reference